Heparin Therapy: Monitoring Coagulation Studies For Safety

Heparin is an anticoagulant used to prevent and treat thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to prevent excess coagulation during procedures such as cardiac surgery, extracorporeal circulation, or dialysis. Heparin is administered intravenously for therapeutic anticoagulation, while subcutaneous administration is used to prevent thromboembolism.

The coagulation study monitored for a patient on heparin is the activated partial thromboplastin time (aPTT). aPTT is a test to determine abnormalities in the extrinsic (factor VII) coagulation pathway. It is a nonspecific test that measures the functional ability of the extrinsic and common coagulation pathways. The test measures plasma clotting time in seconds after the addition of tissue thromboplastin (factor III) and calcium chloride to the specimen.

The therapeutic aPTT for heparin is considered to be 1.5 to 2 times control, which varies from facility to facility based on controls.

Prothrombin Time (PT)

The test is performed by adding calcium and thromboplastin, an activator of the extrinsic pathway, to a blood sample and then measuring the time (in seconds) required for fibrin clot formation. The normal reference range for prothrombin time is typically around 11–13 seconds, although this can vary depending on the laboratory and the reagents used. The results are often reported as an International Normalized Ratio (INR), which standardises the results across different laboratories. The normal INR range for a person not taking blood-thinning medication is 0.8–1.2, while for someone on anticoagulant therapy, the target INR range is typically 2–3.

PT tests are commonly used to monitor patients taking the blood-thinning medication warfarin. They help ensure that the patient is taking the correct dose and is not at risk of excessive bleeding. PT tests can also be used to evaluate liver damage, vitamin K status, and the presence of bleeding or clotting disorders.

The procedure for a PT test involves drawing blood from a vein, usually in the arm or hand. The blood is then mixed with sodium citrate, which acts as an anticoagulant, and centrifuged to separate the blood cells from the plasma. Calcium is added to the plasma sample to reverse the effects of citrate and enable clotting. Finally, tissue factor is added to activate the extrinsic clotting cascade pathway, and the time the sample takes to clot is measured.

PT tests are generally safe, with minimal risks associated with the procedure. However, people with bleeding disorders may have a slightly higher risk of excessive bleeding and hematoma (blood accumulating under the skin). Other possible risks include fainting, lightheadedness, and slight bruising or soreness at the puncture site.

International Normalized Ratio (INR)

The International Normalized Ratio (INR) is a test that measures how long it takes for a person's blood to clot. It is used to monitor patients taking anticoagulants, such as warfarin, to ensure they are within a safe range to prevent blood clots without risking haemorrhaging.

The INR is derived from the prothrombin time (PT) test, which measures how quickly blood clots. The PT results can be expressed as an INR to standardise the results. The INR value is calculated using the following formula:

INR = Patient PT ÷ Control PT

The INR value is dimensionless and typically ranges from 2.0 to 3.0. INR testing is usually carried out every 3-4 weeks for patients on anticoagulants.

INR tests are particularly important for patients taking warfarin, a medicine used to treat and prevent blood clots. Warfarin is prescribed to prevent strokes, treat and prevent deep vein thrombosis and pulmonary embolism, and prevent blood clots in people with artificial heart valves.

If a patient's INR is above the target range, their blood is clotting too slowly, and they are at risk of bleeding. Conversely, if the INR is below the target range, the patient is at an increased risk of developing a blood clot.

It is important to inform your doctor about any medications, supplements, or recent dietary changes, as these factors can influence thesection of warfarin and impact INR results.

While INR testing is commonly used to monitor warfarin therapy, it is not always necessary for patients taking newer anticoagulants.

In summary, the International Normalized Ratio (INR) is a crucial test for monitoring anticoagulant therapy, especially for patients taking warfarin, to ensure that their blood clotting levels are within a safe range.

Activated Partial Thromboplastin Time (aPTT)

• The cause of too much bruising or bleeding
• The cause of clotting problems
• Monitor people taking heparin
• Check the risk for possible bleeding problems before surgery or medical procedures

The aPTT test is considered a more sensitive version of the PTT and is used to monitor the patient's response to heparin therapy. The reference range of the aPTT is 30-40 seconds. If the blood took longer than normal to clot on an aPTT test, it may be a sign of a lack of vitamin K or certain genetic disorders. If the blood clotted faster than normal, it may be a sign of the early stage of disseminated intravascular coagulation (DIC) or extensive cancer.

Activated Clotting Time (ACT)

ACT is commonly used to monitor treatment with high-dose heparin before, during, and for a short time after medical or surgical procedures that require the prevention of blood clotting, such as heart bypass surgery, coronary angioplasty, and dialysis. It is a rapid test that can be performed at the patient's bedside prior to surgery or other medical procedures. ACT testing allows for the measurement of relatively rapid changes in heparin infusion, helping to achieve and maintain a constant level of anticoagulation throughout the surgical or medical procedure.

The sensitivity of the ACT test to heparin depends on the method used. Some ACT tests are designed to monitor lower levels of heparin, while others are best at monitoring high levels. When heparin reaches therapeutic maintenance levels, the ACT is usually replaced as a monitoring tool by the partial thromboplastin time (PTT) test. The PTT test is used to monitor heparin therapy in moderate doses.

The ACT test is also sometimes used to monitor regular-dose heparin therapy in people with documented lupus anticoagulant (LAC). The presence of LAC has been shown to interfere with certain ACT testing, so it is important for the laboratory to follow the manufacturer's instructions and determine if the test is suitable for patients with a history of LAC or antiphospholipid syndrome.

Anti-Factor Xa Assays

The anti-factor Xa assay is a laboratory test that measures the plasma heparin (unfractionated heparin and low-molecular-weight heparin) levels in a patient's blood and monitors their anticoagulant therapy. Heparins are commonly used anticoagulants, and their treatment can be with unfractionated heparin or low-molecular-weight heparin.

The anti-factor Xa assay is predominantly used for monitoring patients treated with low-molecular-weight heparins, especially in cases of extreme weight, pregnancy, critical illness, or renal impairment. This is because low-molecular-weight heparins predominantly affect the activity of factor Xa, so it is appropriate to monitor them with an anti-Xa assay. The measured anti-Xa activity is considered directly proportional to the plasma concentration.

The anti-factor Xa assay is also used to guide the determination of therapeutic activated partial thromboplastin time (aPTT) ranges in the clinical management of unfractionated heparin. The aPTT is the test most often used to monitor heparin, but it is less sensitive to warfarin than the anti-factor Xa assay.

The anti-factor Xa assay can be used to measure levels of heparin and low-molecular-weight heparin. These are chromogenic assays that use a factor Xa substrate onto which a chromophore has been linked. When a known amount of factor Xa is added to plasma containing heparin

Frequently asked questions